Aged-care residents will be among the first to receive the Pfizer vaccine when the rollout begins next week. For some, the process of consenting to the vaccine could raise ethical questions.
Academic rigor, journalistic flair
Articles on Coronavirus vaccines
Displaying 1 - 20 of 66 articles
While some of the authorised COVID-19 vaccines are grown, others are built.
The Oxford/AstraZeneca vaccine is the latest to struggle against the South African variant in trials, while in Israel vaccines may be beginning to have an effect.
Providing multivitamin and mineral supplements to the elderly could be a cheap way of boosting the protectiveness of COVID-19 vaccines.
Chile made a strong case for price reductions, cut deals with multiple providers and participated in trials for early access.
Countries may or may not choose to give their share doses to Covax, but regardless, redistribution needs to be driven by need.
Both vaccines appear to reduce the risk of developing COVID-19, and so could be approved later this year.
Selfishness was also a problem when the world was developing vaccines for swine flu and bird flu.
On the face of it, it seems like a good idea.
Lower than expected deliveries of AstraZeneca vaccines are exposing the bloc's slow rollout.
Production limits the rate at which vaccines can be rolled out, and is at the heart of the current disagreements between the UK and EU.
Israel is vaccinating its population at an impressive rate and sharing the data with the world. But at what price?
We've gone from a novel virus to several COVID-19 vaccines in less than a year. Here's what we've learned from earlier vaccines to allow this to happen.
Vaccines that use harmless viruses as a delivery mechanism are vulnerable to being attacked by our immune system – but experimenting with how they are given could get around this.
History tells us that mass vaccination campaigns are usually messy, while elsewhere, lower-income countries are turning to China, Russia and India for vaccines.
Your chance to ask a panel of experts about the coronavirus variants at 12.30pm GMT on Wednesday January 27.
History tells us that delays, administrative hurdles, messiness and complexity are the norm.
All sorts of transactions are "two-way value exchanges" in which it isn't clear in which direction the money should flow. The proposed media bargaining code is one of them.
As vaccination begins to take effect, what we'll be able to do will change – but the transformation will be slow.
As the coronavirus rages, a vaccine finally is available for certain groups of people and will soon be ready for other groups. But there are plenty of questions. A doctor answers five here.
Top contributors
-
Professorial Fellow, University of Canberra
-
Associate professor, UNSW
-
Professor of Economics, University of Birmingham
-
Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Senior Lecturer in Biochemistry and Cell Biology, University College Cork
-
Associate Professor in Criminology, Swinburne University of Technology
-
Associate Professor, Epidemiology and Environmental Health, University of Canterbury
-
Professor of Law and Public Health, The Ohio State University
-
Senior Lecturer Product Design, University of Technology Sydney
-
Postdoctoral Research Fellow, Australian Catholic University
-
University Research Lecturer, University of Oxford
-
Principal Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Emeritus Professor, Development Studies, University of Oxford
-
Andrew McLachlan is a Friend of The Conversation.
Head of School and Dean of Pharmacy, University of Sydney
